Bioceres Crop Solutions Announces Fiscal Q4 and Full-Year 2026 Financial and Operating Results
Bioceres Crop Solutions Corp. (NASDAQ: BIOX) has reported its financial and operating results for the fourth quarter and full fiscal year ended June 30, 2026, highlighting progress in reducing operating expenses, strengthening its core portfolio and improving profitability despite a challenging year for the agricultural technology company.
Bioceres develops and commercializes agricultural productivity solutions designed to improve crop resilience, support more regenerative farming systems and help growers respond to the effects of climate change. The company reported its fiscal 2026 results in U.S. dollars under International Financial Reporting Standards (IFRS).
The company said fiscal 2026 was marked by significant operational and financial challenges, including ongoing legal proceedings involving certain creditors. Against this backdrop, management focused on concentrating the business around its core capabilities, lowering its cost structure and improving operating discipline.
Pro Farm Group Classified as Discontinued Operations
An important factor in interpreting Bioceres’ latest financial results is the treatment of its Pro Farm Group (PFG) business.
In January 2026, PFG was subject to a foreclosure auction. Bioceres disputes the acceleration of the relevant notes and the foreclosure process, and the matter remains subject to ongoing legal proceedings.
For accounting purposes, PFG has therefore been classified as a discontinued operation. As a result, the continuing-operations figures presented by Bioceres exclude the PFG business, and prior-year financial results have been recast where necessary to provide comparable information.
This accounting treatment allows investors to evaluate the performance of the company’s continuing operations separately from the discontinued business.
Fourth-Quarter Revenue Remains Broadly Stable
Bioceres generated $55.9 million in revenue during the fourth quarter of fiscal 2026, broadly unchanged from the same period a year earlier.
The company said growth in its Crop Nutrition business helped offset weaker Crop Protection revenue and the effects of the ongoing reconfiguration of its Seeds business.
Crop Nutrition revenue increased 36% during the quarter, providing an important contribution to overall performance. The improvement helped Bioceres maintain quarterly revenue despite challenges affecting other areas of the portfolio.
For the full fiscal year, revenue from continuing operations reached $238.3 million, representing an 18% decline from fiscal 2025.
According to the company, approximately half of the annual revenue reduction was associated with the substantially completed reconfiguration of its Seeds business and the resulting decline in HB4-related activities.
Gross Profit Affected by Inventory Adjustment
Bioceres reported fourth-quarter gross profit of $12.7 million, compared with $13.6 million in the fourth quarter of fiscal 2025.
The company noted that the quarterly result included a $4.0 million non-recurring inventory adjustment following an updated assessment of inventory obsolescence.
Management said the adjustment affected reported gross margin and obscured improvements achieved across several important product categories during the quarter.
For fiscal 2026 as a whole, gross profit totaled $82.9 million, down 21% compared with the previous fiscal year.
While several core product categories showed better performance, the overall result was affected by lower contributions from inoculants as well as higher inventory obsolescence charges.
Within Crop Nutrition, the company said the largest decline in gross profit reflected a lower contribution from its Syngenta agreement. This was partially offset by improved contribution from microbeaded fertilizers.
Significant Reduction in Operating Expenses
One of the strongest areas of improvement during fiscal 2026 was Bioceres’ operating expense structure.
Selling, general and administrative expenses fell 19% year-over-year during the fourth quarter, declining by $4.9 million.
For the full fiscal year, SG&A expenses decreased 24% to $71.2 million, representing a reduction of $22.5 million compared with fiscal 2025.
The company attributed these reductions to cost-control measures introduced throughout the year. The lower fixed and variable expense base allowed Bioceres to offset some of the pressure created by lower revenue and gross profit.
The company’s management believes these actions have created a more focused operating structure and could provide a stronger foundation for future profitability.
Adjusted EBITDA Returns to Positive Territory
Bioceres also reported a significant improvement in Adjusted EBITDA during the fourth quarter.
Adjusted EBITDA improved by $10.1 million, moving from negative $9.6 million in the fourth quarter of fiscal 2025 to positive $0.6 million in fiscal 4Q26.
Management attributed the improvement primarily to the substantially lower operating expense base.
Net loss from continuing operations also improved considerably during the quarter. The company reported a net loss of $31.8 million, compared with a $54.4 million loss in the corresponding period of fiscal 2025.
For the full fiscal year, however, net loss from continuing operations was $54.4 million, compared with $49.1 million in fiscal 2025.
Full-year Adjusted EBITDA stood at $25.5 million, compared with $28.9 million in the prior fiscal year.
Management Focuses on Portfolio and Commercial Strategy
Federico Trucco, Chief Executive Officer of Bioceres Crop Solutions, described fiscal 2026 as a challenging year but said the fourth-quarter results provided evidence that the company’s restructuring and cost-control initiatives are beginning to produce results.
Trucco said the company’s priorities during the year were to focus on its core capabilities, reduce expenses and strengthen operational discipline.
The CEO pointed to stable fourth-quarter revenue from continuing operations, improved performance across several core product categories and the company’s return to positive Adjusted EBITDA as encouraging developments.
Bioceres has also substantially completed the nearly two-year reconfiguration of its Seeds business.
In addition, the company has completed an external strategic assessment of its continuing operations. Management said this process has produced a roadmap for the next phase of the business.
The strategy includes rationalizing the company’s product portfolio and go-to-market channels, reviewing certain commercial policies and strategic relationships, and aligning research, development and regulatory investments with clearly defined financial objectives.
Bioceres also plans to continue identifying opportunities to improve its operating expense structure.
Source Link:https://www.businesswire.com/
